Modified stem cells and CAR T cells for hard-to-treat AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new approach for people with acute myeloid leukemia (AML) that has not gotten better with standard treatments. First, you receive modified stem cells, then specially designed immune cells (CAR T cells) that target a protein called CD33 on leukemia cells. The goal is to see if this combination can safely help your body fight the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your AML has not responded to other treatments, or has come back after a stem cell transplant.
- You have a suitable stem cell donor available.
- Your heart, kidneys, liver, and lungs are working well enough (tests will be done to check).
- You are able to care for yourself (ECOG performance status 0 or 1) and not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy, called CAR-T, that uses your own immune cells to find and attack leukemia cells. It's designed for people whose AML has come back or hasn't responded to standard treatments. The cells are modified to target a protein called CD33 on leukemia cells.
This trial tests a new type of cell therapy using natural killer (NK) cells that target a protein called CD33 found on AML cells. The goal is to see if these cells can help treat leukemia that has not responded to standard treatments, and you would receive a stem cell transplant afterward to help your bone marrow recover.
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
This study tests a new treatment made from your own immune cells, engineered to find and attack AML cells. It is for patients whose leukemia has not responded to standard therapy or has come back after treatment, including after a stem cell transplant.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests a new type of CAR-T cell therapy that targets two proteins on leukemia cells (called CLL1 and CD33). The goal is to help people with acute myeloid leukemia that has relapsed or not responded to standard treatments.
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.